We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Distinct Mutation Patterns Identified in Appendiceal Cancer

By LabMedica International staff writers
Posted on 24 Dec 2020
The incidence of appendiceal cancer (AC) is rising, particularly among individuals younger than 50 years (early-onset AC), with unexplained etiologies. More...
The unique spectrum of somatic cancer gene variations among patients with early-onset AC is largely undetermined.

Appendiceal cancer is a rare neoplasm, with an age-adjusted incidence rate of 0.97 per 100,000. The incidence of appendiceal cancer has increased by 54%. Histologically, this malignancy accounts for 0.5%-1% of all biopsy specimens following appendectomies. Most patients will present with distant metastatic disease with significant tumor burden in the peritoneum, placing them at higher risk for bowel obstruction and increased morbidity and mortality.

Medical Scientists at the Vanderbilt University Medical Center (Nashville, TN, USA) included in a cohort study individuals aged 18 years and older diagnosed with pathologically verified AC. In total 385 individuals (mean ± SD) age at diagnosis, 56.0 ±12.4 years; (187 [48.6%] men; 306 [79.5%] non-Hispanic White individuals) with AC were included in this study, and 109 patients (28.3%) were diagnosed with early-onset AC. Somatic variation data in tumor tissues was generated using clinical-grade targeted gene panel sequencing approaches from different sequencing centers. Median sequencing depth (pooled median read depth, 500×) was determined.

The investigators reported that in contrast to late-onset cases, which tended to be marked by recurrent, non-silent alterations in the GNAS gene, they saw a significant dip in GNAS variants in tumors from individuals with early-onset disease. Instead, appendiceal cancer tumors from the younger patients tended to contain more non-silent variants in genes such as PIK3CA, SMAD3, and TSC2.

Compared to the corresponding late-onset cases, the team documented declines in GNAS mutations from early-onset appendiceal cancers from both the mucinous and non-mucinous histological subtypes of appendiceal adenocarcinoma, though the proportion of those variants differed slightly by subtype. In the sample set considered, the investigators only detected GNAS gene mutations in early- and late-onset tumors lacking TP53 mutations, while TP53 mutations were limited to GNAS mutation-free tumors, suggesting these changes are likely mutually exclusive.

Xingyi Guo, PhD, an assistant professor of medicine and senior author of the study, said, “Appendiceal cancer diagnosed among younger individuals harbored a distinct genomic landscape compared with appendiceal cancer diagnosed among older individuals. Development of therapeutic modalities that target these unique molecular features may yield clinical implications specifically for younger patients.”

The authors concluded that their study had found a distinct spectrum of somatic variations among early-onset AC cases, as younger patients had higher odds of presenting with PIK3CA, SMAD3, and TSC2 somatic variations and decreased odds of presenting with GNAS variations compared with late-onset AC cases. These findings demonstrate that ACs diagnosed among young individuals harbor a distinct molecular phenotype compared with late-onset ACs.

The study was published on December 9, 2020 in the JAMA Network Open.

Related Links:
Vanderbilt University Medical Center


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.